Evidence map›Paper›PMID 25539909›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2014

Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.

Mohsen Vosooghi, Loghman Firoozpour, Abolfazl Rodaki, Mahboobeh Pordeli, Maliheh Safavi, Sussan K Ardestani, Armin Dadgar, Ali Asadipour, Mohammad Hassan Moshafi, Alireza Foroumadi

Abstract readComparative Study
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Inappropriate use of the term "cytotoxicity" in scientific literature.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohsen VosooghiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. vosoghim@tums.ac.ir.
Loghman FiroozpourDrug Design and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran. Firoozpour@gmail.com.
Abolfazl RodakiDrug Design and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran. r_rodaki@yahoo.com.
Mahboobeh PordeliInstitute of Biochemistry and Biophysics, University of Tehran, PO Box 13145-1384, Tehran, Iran. pordeli@ibb.ut.ac.ir.
Maliheh SafaviDepartment of Biotechnology, Iranian Research Organization for Science and Technology, Tehran, Iran. safavi_maliheh@yahoo.com.
Sussan K ArdestaniInstitute of Biochemistry and Biophysics, University of Tehran, PO Box 13145-1384, Tehran, Iran. ardestany@ut.ac.ir.
Armin DadgarDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a.dadgar@gmail.com.
Ali AsadipourNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medicinal Sciences, Kerman, Iran. aliasadipour@yahoo.com.
Mohammad Hassan MoshafiNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medicinal Sciences, Kerman, Iran. moshafi14@yahoo.com.
Alireza ForoumadiNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medicinal Sciences, Kerman, Iran. aforoumadi@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is the most common type of female cancer. One class of hormonal therapy for breast cancer drugs -non steroidal aromatase inhibitors- are triazole analogues. In this work, some derivatives of these drugs was designed and synthesized. All synthesized compounds were evaluated for their cytotoxic activities on breast cancer cell lines (MDA-MB-231, T47D and MCF-7).

methodsOur synthetic route for designed compounds started from 4-bromotolunitrile which was reacted with 1H-1,2,4-triazole to afford 4-(4-cyanobenzyl)-1,2,4-triazole. The reaction of later compound with aromatic aldehydes led to formation of the designed compounds. Eleven novel derivatives 1a-k were tested for their cytotoxic activities on three human breast cancer cell lines.

resultsAmong the synthesized compound, 4-[2-(3-chlorophenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile (1c) showed the highest activity against MCF-7 and MDA-MB-231 cell lines and 4-[2-(4-methoxyphenyl)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile (1 h) exhibited highest activity against T47D cell line. According to cytotoxic activities results, compound 4-[2-(4-dimethylamino)-1-(1H-1,2,4-triazol-1-yl)ethenyl]benzonitrile (1 k) showed comparative activity against T47D and MDA-MB-231 cell lines with compound (1 h) and our reference drug Etoposide.

conclusionIn the process of anti-cancer drug discovery, to find new potential anti-breast cancer agents, we designed and synthesized a novel series of letrozole analogs. Cytotoxicity evaluation revealed that compounds (1c) and (1 k) were the most potent compounds with comparative activity with Etoposide. The results revealed that π-π interactions are responsible for the enzyme inhibitions of compounds (1 c) and (1 k).

Indexed as

Computer-Aided DesignDrug DesignMolecular Docking SimulationAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsCell ProliferationCell SurvivalDose-Response Relationship, DrugFemaleHumansInhibitory Concentration 50LetrozoleMCF-7 CellsMolecular StructureNitrilesAntineoplastic Agents, HormonalAromatase InhibitorsLetrozoleNitrilesTriazoles

Identifiers

PMID25539909
PMCPMC4284924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.